Sai Parenterals Board Approves Q4 FY26 & 9MFY26 Results, Auditors Issue Unmodified Opinion
Sai Parenterals Limited's Board approved Q4 FY26 and 9MFY26 results on May 23, 2026. Standalone 9MFY26 revenue was ₹105.46 crore, with PAT ₹8.28 crore. Consolidated 9MFY26 revenue was ₹153.07 crore, with PAT ₹1.10 crore. Audited FY26 standalone revenue ₹124.27 crore, PAT ₹99.49 crore. Consolidated FY26 revenue ₹350.99 crore, PAT ₹131.57 crore. Auditors issued an unmodified opinion.
The announcement includes the approval of financial results for two periods and an unmodified audit opinion, which are material disclosures for investors. The ongoing IPO process also adds to the significance.
The company reported financial results and received an unmodified audit opinion, which are positive indicators.
Sai Parenterals Limited announced the outcome of its Board Meeting held on May 23, 2026. The Board considered and approved the Un-audited financial results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025, along with the Limited Review Report for the same period. Additionally, the Board approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026, along with the Auditors Report, which included a declaration of unmodified opinion from the statutory auditors, R Kabra & Co. LLP. The Board meeting commenced at 11:30 a.m. and concluded at 4:15 p.m.
For the nine months ended December 31, 2025, standalone revenue from operations was ₹105.46 crore, with a profit after tax of ₹8.28 crore. Consolidated revenue from operations for the same period was ₹153.07 crore, with a profit after tax of ₹1.10 crore.
For the year ended March 31, 2026, standalone revenue from operations was ₹124.27 crore, and the profit after tax was ₹99.49 crore. Consolidated revenue from operations for the year ended March 31, 2026, was ₹350.99 crore, with a profit after tax of ₹131.57 crore.
The company also noted that it has filed the Draft Red Herring Prospectus (DRHP) for its Initial Public Offer (IPO). The auditors have issued an unmodified conclusion on the financial results.
What to do with a filing like this
Sai Parenterals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Parenterals Limited. Read the original for the full detail.